Characterization of Spore Proteins Using a Nanoscaffold Vaccine Platform.

Clicks: 254
ID: 109596
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #53 of 111 articles by views in Frontiers in immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Subunit vaccines are theoretically safe and easy to manufacture but require effective adjuvants and delivery systems to yield protective immunity, particularly at critical mucosal sites such as the lung. We investigated nanolipoprotein particles (NLPs) containing the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) as a platform for intranasal vaccination against . Modified lipids enabled attachment of disparate spore and toxin protein antigens. Intranasal vaccination of mice with antigen-MPLA-NLP constructs induced robust IgG and IgA responses in serum and in bronchoalveolar and nasal lavage. Typically, a single dose sufficed to induce sustained antibody titers over time. When multiple immunizations were required for sustained titers, specific antibodies were detected earlier in the boost schedule with MPLA-NLP-mediated delivery than with free MPLA. Administering combinations of constructs induced responses to multiple antigens, indicating potential for a multivalent vaccine preparation. No off-target responses to the NLP scaffold protein were detected. In summary, the NLP platform enhances humoral and mucosal responses to intranasal immunization, indicating promise for NLPs as a flexible, robust vaccine platform against and potentially other inhalational pathogens.
Reference Key
weilhammer2020characterizationfrontiers Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Weilhammer, Dina R;Dunkle, Alexis D;Boone, Tyler;Gilmore, Sean F;Khemmani, Mark;Peters, Sandra K G;Hoeprich, Paul D;Fischer, Nicholas O;Blanchette, Craig D;Driks, Adam;Rasley, Amy;
Journal Frontiers in immunology
Year 2020
DOI
10.3389/fimmu.2020.01264
URL
Keywords
vaccine anthrax monophosphoryl lipid a (mpla) nanolipoprotein particle (nlp) nanoscaffold spore antigens

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.